DadFinStart your free week
DadFin › Stocks › Healthcare › SIGA

SIGA Technologies, Inc. (SIGA) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$3.28 +0.00% today

64.6
Dad Score, out of 100
middling

SIGA Technologies, Inc. (SIGA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 64.6 out of 100 on the Dad Score, a middling reading that places the business ahead of 65% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #301 of 974. Its strongest axes are valuation, price action and conviction; its weakest are quality and growth.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Weak
Growth
Weak
Price action
Above average
Risk
Average
Conviction
Strong
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)3.1×
Dividend yield0.00%
Return on capital15.1%
Operating margin33.9%
Revenue growth (YoY)-31.8%
FCF yield49.1%
Net debt / EBITDA3.00×
Piotroski F-Score4 / 9
52-week change-53.6%
Market cap$243M
Next earnings—

What subscribers see on SIGA

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.